DavidMWeinstockMD

PubMed

• Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
  Steven M Horwitz, Ajit J Nirmal, Jahan Rahman, Ran Xu, Esther Drill
  Nature Medicine. 2024-12-01
• Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
  Steven M Horwitz, Ajit J Nirmal, Jahan Rahman, Ran Xu, Esther Drill
  Nature Medicine. 2024-09-01
• 2 citations
  Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.
  Edward L Briercheck, Shashidhar Ravishankar, Elshafa Hassan Ahmed, César Camilo Carías Alvarado, Juan Carlos Barrios Menéndez
  Blood Advances. 2024-07-23

Journal Articles

• Clinicogenetic risk modeling in ATL  
  Yoshida N, Weinstock DM, Blood, 1/1/2018
• Outcomes After Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma  
  Herrera AF, Rodig, SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen Y-B, Chan WC, Cutler CS, H..., Biol Blood Marrow Transplant, 1/1/2018
• Activity of the PI3K-delta,gamma inhibitor Duvelisib in a phase I trial and preclinical models of T-cell lymphoma  
  Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster ..., Blood, 1/1/2018
• Co-targeting JAK/STAT and mTORC1/ C2 signaling produces synergistic activity in Philadelphia chromosome�like acute B-cell lymphoblastic leukemia  
  Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Tai C, Cavazos A, Park E, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu S-C, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Ra..., Oncotarget, 1/1/2018
• An �off-the-shelf� fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies  
  Cooper M, Choi J, Staser K, Ritchey J, Niswonger J, Eckardt K, Rettig M, Wang B, Eissenberg L, Ghobadi A, Gehrs L, Prior J, Achilefu S, Miller C, Fronick C, O�Neal J, ..., Leukemia, 1/1/2018
• B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignancies  
  Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jian..., Cell, 1/1/2018
• Genomic analyses identify recurrent PD-L1/PD-L2 structural variants in cutaneous diffuse large B-cell lymphomas  
  Zhou XA, Wenzel A, Louissaint A, Yang J, Martinez-Escala ME, Guitart J, Behdad A, Cerroni L, Weinstock DM, Choi J, J Invest Dermatol, 1/1/2018
• Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reac...  
  Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vital..., Brit J Haematol, 1/1/2018
• Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models  
  Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, ..., Nat Commun, 1/1/2018
• RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice  
  Ng SY, Brown L, Stevenson KE, Aster JC, DeSouza T, Louissaint, Weinstock DM, Blood, 1/1/2018
• Assessment of CD52 expression in �Double-hit� and �Double-expressor� lymphomas: implications for clinical trial eligibility  
  Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, Pozdnyakova O, PLoS One, 1/1/2018
• Parp3 promotes long-range end-joining in murine cells  
  Layer JV, Cleary JP, Brown AJ, Stevenson KE, Van Scoyk A, Morrow SN, Blasco RB, Karaca E, Meng F-L, Frock RL, Tivey T, Kim S, Fuchs H, Chiarle R, Alt FW, Roberts SA, W..., Proc Natl Acad Sci USA, 1/1/2018
• Targeting minimal residual disease: a path to cure?  
  Luskin M, Murakami MA, Manalis SR, Weinstock DM, Nature Reviews Cancer, 1/1/2018
• Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation  
  Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedma..., J Clin Onc, 1/1/2017
• Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia  
  Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee AS, Place AE, Kim S, Saran C, Modiste R, Weinstock DM, Harris M, Kung AL, Silverman LB, Stegmaier K, Clin Cancer Res, 1/1/2017
• Anti-leukemic Activity of the TYK2 selective inhibitor NDI-031301 in T-cell Acute Lymphoblastic Leukemia  
  Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwoods JR, Tiv H, Sanda T, Weinstock DM, Look AT, Brit J Haematol, 1/1/2017
• Deletion of ribosomal protein genes is a common vulnerability in human cancer, particularly in concert with TP53 mutation  
  Ajore R, Raiser D, McConkey M, Joud M, Boidol B, Mar B, Saksena G, Weinstock DM, Armstrong S, Ellis SR, Ebert BL, Nilsson B, EMBO Mol Med, 1/1/2017
• PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA  
  Day TA, Layer JV, Cleary JP, Guha S, Stevenson KE, Tivey T, Kim S, Schinzel AC, Izzo F, Doench J, Root DE, Hahn WC, Price BD, Weinstock DM, Nature Commun, 1/1/2017
• Escape from X-Inactivation Tumor Suppressor (EXITS) genes contribute to cancer sex bias  
  Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA, Nat Genet, 1/1/2017
• Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas  
  Rolland DCM, Basrur V, Jeon YK, McNeil-Schwalm C, Fermin D, Conlon KP, Zhou Y, Ng SY, Tsou CC, Brown NA, Thomas DG, Bailey NG, Omenn GS, Nesvizhskii AI, Root DE, Weins..., Proc Natl Acad Sci, 1/1/2017
• Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase  
  Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, G..., Oncotarget, 1/1/2017
• Constitutive Ras Signaling and Ink4a/Arf Inactivation Cooperate During the Development of B-ALL in Mice  
  Sewastianik T, Jiang M, Sukhdeo K, Patel SJ, Roberts K, Kang Y, Alduaij A, Dennis PS, Lawney B, Liu R, Song Z, Xiong J, Zhang Y, Lemieux ME, Pinkus G, Rich JN, Weinsto..., Blood Advances, 1/1/2017
• Inhibition of USP10 induces degradation of oncogenic FLT3: a novel approach to therapy of leukemia  
  Weisberg EL, Schauer N, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Goghale PC, Ritorto MS, De Cesar V, Trost M, Christodoulou ..., Nat Chem Biol, 1/1/2017
• PDX-MI: minimal information for patient-derived tumor xenograft models  
  Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, ..., Cancer Res, 1/1/2017
• It takes a village to unmask HSTL  
  Yoshida N, Weinstock DM, Cancer Disc, 1/1/2017
• Join now to see all

Books/Book Chapters

• Disaster Medicine: Comprehensive Principles and Practice 
  Chapter: Radiation accidents and the medical management of acute radiation injury 
  Page 545.0 - 579.0Hatchett RJ, Weinstock DM, Goans REEditors: Koenig and Schultz.Cambridge University Press, New York, NY2016
• Principles and Practices of Infectious Diseases 
  Chapter: Epstein-Barr Virus, Varicella-Zoster Virus and Human Herpes Viruses-6 and -8 
  Page 359.0 - 370.0Kamboj M, Weinstock DMEditors: Safdar A.Humana Press, New York, NY2011
• Multidrug-resistant tuberculosis 
  Chapter: Multidrug-resistant tuberculosis and the health care worker 
  Page 225.0 - 240.0Weinstock DM, Sepkowitz KAEditors: Bastian I, Portaels F.Kluwer Academic Publishers, Dordrecht, The Netherlands2000

Abstracts/Posters

• DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia
  David M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Future collaboration with CTCL
  Weinstock D, Cutaneous Lymphoma International Consortium Investigator Meeting, St. Gallen, Switzerland, 1/1/2018
• Join now to see all

Lectures

• Aggressive Lymphomas 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Forum on Patient-Derived Models: What�s Next 
  DFCI, Boston, MA - 1/1/2018
• Targeting vulnerabilities in lymphoid neoplasms 
  Waltham, MA, 2018; Boston University Medical Center, Boston, MA, 2018; Brigham and Women�s Hospital, - 1/1/2018
• Targeting vulnerabilities in high-risk lymphoid neoplasms 
  Waltham, MA - 1/1/2018
• What is the molecular basis and most promising road towards molecular targeted therapies for double-hit lymphoma? 
  Boston, MA - 1/1/2018
• Translocation models for T-cell lymphoma 
  Boston, MA - 1/1/2018
• Interrogating the xenograft microenvironment 
  Chicago, IL - 1/1/2018
• Functional approaches to target lymphomas 
  Scottsdale, AZ - 1/1/2018
• Defining and targeting vulnerabilities in T cell lymphomas 
  Philadelphia, PA - 1/1/2018
• Expert Stakeholder Panel on Innovative Financing 
  Washington, DC - 1/1/2018
• Genomics of T-cell lymphomas 
  San Diego, CA - 1/1/2018
• New Strategies for Cancer Translation 
  Rennes, France - 1/1/2018
• The Public Repository of Xenografts 
  University of Copenhagen, Copenhagen, Denmark - 1/1/2018
• Defining Vulnerabilities of PTCL 
  Bologna, Italy - 1/1/2018
• Co-Clinical Trials with PDX models 
  Stockholm, Sweden - 1/1/2018
• How to predict responses in silico and in vitro? 
  European School of Hematology, Saggart (Dublin), Ireland - 1/1/2018
• Approaches to advance precision medicine and immune-oncology in hematologic malignancies 
  Seville, Spain - 1/1/2018
• The Weinstock Laboratory 
  BCH, Boston, MA - 1/1/2017
• Public Repository of Xenografts 
  Department of Pediatric Oncology, DFCI, Boston, MA - 1/1/2017
• Turning Responses into Cures 
  DFCI, Boston, MA - 1/1/2017
• Suspended Microchannel Resonators for Assaying Minimal Residual Disease (MRD) 
  DF/HCC, Boston, MA - 1/1/2017
• Targeting Peripheral T-cell Lymphomas 
  Broad Institute, Cambridge, MA - 1/1/2017
• Can Smarter Models Help Cure Cancer 
  Boston, MA - 1/1/2017
• Is it Possible to Model Cure of ALL? 
  Boston, MA - 1/1/2017
• T-cell Lymphomas 
  Boston, MA - 1/1/2017
• Join now to see all

Other

• Modeling Human Immunity and Disease 
  Weinstock D, CellPress Webinar
  http://view6.workcast.net/register?cpak=6477842955389592&referrer=webinarpage
  1/1/2017
• Navigating Future Challenges in Lymphoma: A Map for the Road Ahead 
  LaCasce A, Weinstock DM, The Hematologist
  1/1/2015
• �Health care loans� for Hep C Cure 
  Andrew Lo, David Weinstock, Boston Globe
  1/25/2016
• Developing more efficient financing methods for healthcare is a matter of life and death 
  Andrew Lo, David Weinstock, Investment News
  1/23/2016
• State of the Art: Management of Rhodococcus equi infections [Perspectives, Contemporary Topics] 
  Weinstock DM, MD Consult Infectious Disease
  http://www.mdconsult.com
  1/26/2002
• State of the Art: Infections among Liver Transplant Recipients [Perspectives, Contemporary Topics] 
  Crawford CV, Weinstock DM, MD Consult Infectious Disease
  http://www.mdconsult.com
  1/28/2003
• Join now to see all